DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Kelleher DL, Hicks KJ, Cox DS. et al
Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS).
Neurogastroenterol Motil 2008; 20: 1-144
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.